At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
INAB IN8bio, Inc.
Market Closed 05-17 16:00:00 EDT
1.03
+0.01
+0.98%
盘后1.03
+0.000.00%
19:30 EDT
High1.05
Low1.02
Vol37.48K
Open1.04
D1 Closing1.02
Amplitude2.94%
Mkt Cap45.34M
Tradable Cap26.28M
Total Shares44.02M
T/O38.71K
T/O Rate0.15%
Tradable Shares25.52M
P/B--
ROE--
EPS0.00
52wk High--
52wk Low--
P/E--
Dividend--
Div.Yield--
ROA--
IN8bio Announces Upcoming Presentation at 2024 European Hematology Association Congress
IN8bio, Inc., a clinical-stage biotechnology company, focuses on developing novel therapies for the treatment of cancers, including solid tumors using allogeneic, autologous, and genetically modified gamma-delta T cells. It is conducting two investigator-initiated Phase 1 clinical product candidates comprising INB-200, a genetically modified autologous gamma-delta T cell product candidate for the treatment of solid tumors; and INB-100, an allogeneic product candidate for the treatment of patients with acute leukemia undergoing hematopoietic stem cell transplantation. The company was formerly known as Incysus Therapeutics, Inc. and changed its name to IN8bio, Inc. in August 2020. IN8bio, Inc. was founded in 2016 and is based in New York, New York.